TAS-303 also showed some evidence of improved incontinence amount, PGI-I scores, and I-QOL scores vs placebo, although the between-group differences did not reach statistical significance (Table 4 ).
← all excerpts
Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
1
—
—